ClinicalTrials.gg
CompletedNCT01919801Updated Jun 8, 2021Results posted

Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema

A Phase 3 interventional study of Icatibant and Placebo in Angiotensin Converting Enzyme Inhibitor Induced Angioedema, sponsored by Shire. Completed at 55 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-08.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies in Angioedema with a site in United States — 8 open to participants now, 10 under way, 4 of them phase 3. Angioedema · United States.

Enrollment
5th of 26
118 · median 49
Started
2013
the only one that year
Phase 3
9 of 32
3 open now
Registered
11th of 32
by date
Lead sponsor
6 of 32
Shire

Among the 32 studies in Angioedema with a site in United States, this one is the 5th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2013, is one of 9 in phase 3, and was the 11th registered.

Angioedema

69 studies on the registry are indexed under Angioedema; 16 are open to participants now.

Browse Angioedema studies →

Open to participants now

8 of the 32 studies in Angioedema with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Angioedema studies recruiting now, 10 (77%) set no upper age limit and 2 (15%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Angioedema with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to compare the safety and efficacy of icatibant with placebo in the treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults.

Read the detailed description

Angiotensin-converting enzyme inhibitors (ACE-Is) are the class of medications prescribed most frequently for the treatment of hypertension. They are also used post myocardial infarction as well as in patients with heart failure, diabetes mellitus, and chronic kidney disease. Approximately 35 to 40 million patients are on ACE-Is worldwide.

Study HGT-FIR-096 is a multicenter, Phase III, randomized, double-blind, two-armed, placebo-controlled trial. The study population will consist of 118 adult patients, 18 years of age or older, who present with an acute ACE-I-induced angioedema attack. The primary aim of the study is to demonstrate that icatibant is significantly more effective than placebo in resolving attacks of angioedema caused by ACE-I based on the Time to Meeting Discharge Criteria (TMDC). Safety and tolerability, as well as the pharmacokinetics (PK), of icatibant will also be evaluated. Eligible patients will be randomized at a 1:1 ratio to receive a single sub-cutaneous injection of either 30 mg icatibant or placebo.

03

Conditions studied

  • Angiotensin Converting Enzyme Inhibitor Induced Angioedema

Browse trials for

Keywords

  • icatibant
  • Firazyr
  • ACE-I
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 18 years of age or older.
  2. Patient is currently being treated with an ACE inhibitor.
  3. Patient presenting with an ACE inhibitor-induced angioedema attack of the head and/or neck region within 12 hours of onset (must be sufficiently less than 12 hours to allow study drug to be given with 12 hours of attack onset).
  4. Angioedema must be considered at least moderate in severity for at least one of the four angioedema-associated airway symptoms (difficulty breathing, difficulty swallowing, voice changes, tongue swelling).
  5. Patient must have voluntarily signed an Institutional Review Board/Independent Ethics Committee-approved form after all relevant aspects of the study have been explained and discussed with the patient.
  6. Females must have a negative urine pregnancy test prior to administration of the study medication, with the exception of those females who have had a total hysterectomy or bilateral oophorectomy, or who are 2 years .

Exclusion criteria

Exclusion Criteria:

  1. Patient has a diagnosis of angioedema of other etiology (eg, hereditary or acquired angioedema, allergic angioedema [eg, food, insect bite or sting, evident clinical response to antihistamines and/or ], anaphylaxis, trauma, abscess or infection or associated disease, local inflammation, local tumor, post-operative or post-radiogenic edema, salivary gland disorders, other [non-ACE inhibitor] drug-induced angioedema).
  2. Patients with a family history of recurrent angioedema.
  3. Patients who have had a previous episode(s) of angioedema while not on ACE inhibitor therapy.
  4. Patients with acute urticaria (itchy, erythematous wheals).
  5. Patients who have an intervention to support the airway (eg, intubation, tracheotomy, cricothyrotomy) due to the current attack of angioedema.
  6. Patient has any of the following vascular conditions that, in the judgment of the investigator, would be a to participation in the study.

    • Unstable angina pectoris or acute myocardial ischemia
    • Hypertensive urgency or emergency (diastolic blood pressure [DBP] >120 mm Hg or systolic blood pressure [SBP] >180 mm Hg)
    • Within 1 month of a stroke or
    • (NYHA) heart failure class IV
  7. Patient has a serious or acute condition or illness that, in the judgment of the investigator, would interfere with evaluating the safety and/or efficacy assessments of the study (eg, a condition or illness requiring hemodialysis).
  8. Patient is pregnant or breast feeding.
  9. Patient has participated in another study in the past 30 days.
  10. Patient is unable to understand the nature, scope, and possible consequences of the protocol, or is unlikely or unable to comply with the protocol assessments, or is unlikely to complete the study for any reason.
  11. Patients who are not suitable for the study in the opinion of the investigator.
  12. Patient has experienced to the active substance of the investigational product or to any of its .
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    Icatibant

    Icatibant at a dose of 30 mg will be administered as a single subcutaneous injection

    Drug: Icatibant

  • Placebo comparator
    Placebo

    Placebo will be administered as a single subcutaneous injection

    Drug: Placebo

Interventions

  • Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema

    Also known as: Firazyr

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Time to Meeting Discharge Criteria (TMDC)

    TMDC was based on the investigator-assessed angioedema-associated upper airway symptom assessments. It was calculated from the time of study drug administration to the earliest time point at which the symptoms of difficulty breathing and difficulty swallowing were absent and the symptoms of voice change and tongue swelling were mild or absent and all subsequent assessments continued to satisfy these conditions. These symptoms were evaluated by the investigator using a 5-point grading scale (0=absent, 1=mild, 2=moderate, 3=severe, and 4=very severe). TMDC was analysed using Kaplan-Meier estimates.

    Time frame: Day 0 up to Day 5

  2. Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as adverse events/serious adverse events that started or worsened after the study drug treatment.

    Time frame: From start of study drug administration (Day 0) up to follow-up (Day 5)

  3. Number of Participants With Treatment Emergent Injection Site Reaction

    Injection site reaction included erythema, swelling, cutaneous pain, burning sensation, itching and warm sensation

    Time frame: Day 0 to Day 5

  4. Number of Participants With Clinically Significant Changes in Laboratory Evaluation, Vital Signs, Electrocardiogram (ECG) and Physical Examination

    During laboratory evaluation, serum chemistry and hematology blood tests, and urinalysis were performed. Vital signs parameters included evaluation of pulse rate and systolic and diastolic blood pressure. Standard 12-lead ECGs were performed and ECG recordings were read locally at the study site by a cardiologist. Physical examination was performed with examination of major body systems per routine clinical practice.

    Time frame: Day 0 to Day 5

Secondary outcomes

  1. Time to Onset of Symptom Relief (TOSR)

    TOSR was calculated for the individual symptoms with pre-treatment scores of 2 (moderate) or more improved by at least 1 severity grade and the individual symptoms with pretreatment scores of 0 or 1 (absent or mild) were scored again at 0 or 1 and all the subsequent assessments continued to satisfy this condition. Time-to-event data were summarized using Kaplan-Meier estimates.

    Time frame: Day 0 up to Day 5

  2. Number of Participants Experienced Airway Intervention Due to ACE-I-induced Angioedema

    Airway Intervention included intubation, tracheotomy, cricothyrotomy.

    Time frame: Day 0 up to Day 5

  3. Number of Participants Admitted to Hospital or Intensive Care Unit (ICU)

    Number of participants with and without an occurrence of admission to the hospital (inpatient) or ICU post-treatment due to the ACE-I-induced angioedema attack were described.

    Time frame: Day 0 up to Day 5

  4. Number of Participants Experienced ACE-I-induced Angioedema Attack Following Study Drug Administration

    Number of participants with the use of conventional medications (corticosteroids, antihistamines, epinephrine) for the treatment of symptoms of the ACE-I- induced angioedema attack following study drug administration were presented.

    Time frame: Day 0 up to Day 5

  5. Percentage of Participants With Time to Meeting Discharge Criteria (TMDC) at Specified Time Points

    TMDC was based on the investigator-assessed angioedema-associated upper airway symptom assessments. It was calculated from the time of study drug administration to the earliest time point at which the symptoms of difficulty breathing and difficulty swallowing were absent and the symptoms of voice change and tongue swelling were mild or absent and all subsequent assessments continued to satisfy these conditions. These symptoms were evaluated by the investigator using a 5-point grading scale (0=absent, 1=mild, 2=moderate, 3=severe, and 4=very severe). TMDC was analysed using Kaplan-Meier estimates.

    Time frame: 4, 6, and 8 hours post treatment

Other outcomes

  1. Area Under the Plasma Concentration Versus Time Curve (AUC) of Icatibant and Its Metabolites (M1 and M2)

    Area under the plasma concentration-time curve of Icatibant and its metabolites (M1 and M2) were analyzed. A population pharmacokinetic analysis approach using sparse pharmacokinetic sampling obtained from a subset of subjects was used to evaluate exposure to icatibant.

    Time frame: 0.75 and 2 hours post-dose

07

Results

Posted Oct 10, 2016

Participant flow

The study was conducted at 59 sites in the United States, United Kingdom, Israel and Canada.

Participant flow — Overall Study
MilestoneIcatibant 30 mgPlacebo
Started6160
Completed6057
Not completed13
Withdrew: Withdrawal by subject10
Withdrew: Physician decision01
Withdrew: Lost to follow-up01
Withdrew: Other01

Outcome measures

PrimaryTime to Meeting Discharge Criteria (TMDC)

TMDC was based on the investigator-assessed angioedema-associated upper airway symptom assessments. It was calculated from the time of study drug administration to the earliest time point at which the symptoms of difficulty breathing and difficulty swallowing were absent and the symptoms of voice change and tongue swelling were mild or absent and all subsequent assessments continued to satisfy these conditions. These symptoms were evaluated by the investigator using a 5-point grading scale (0=absent, 1=mild, 2=moderate, 3=severe, and 4=very severe). TMDC was analysed using Kaplan-Meier estimates.

Time frame:
Day 0 up to Day 5
Reported as:
Median · days
Time to Meeting Discharge Criteria (TMDC)
daysIcatibant 30 mgPlacebo
Time to Meeting Discharge Criteria (TMDC)4.03 (2.03 to 6.00)4.00 (1.03 to 6.00)
Statistical analysis
  • Icatibant 30 mg vs Placebo · Adjusted Peto-Prentice · p = 0.633 (Test was performed using a weighted log-rank test called the Peto-Prentice test with a global 2-sided significance level of 5% after adjusting for stratification factors (race, and severity) in the ITT population.)
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as adverse events/serious adverse events that started or worsened after the study drug treatment.

Time frame:
From start of study drug administration (Day 0) up to follow-up (Day 5)
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs)
participantsIcatibant 30 mgPlacebo
Participants with TEAEs2721
Participants with TESAEs21
PrimaryNumber of Participants With Treatment Emergent Injection Site Reaction

Injection site reaction included erythema, swelling, cutaneous pain, burning sensation, itching and warm sensation

Time frame:
Day 0 to Day 5
Reported as:
Number · participants
Number of Participants With Treatment Emergent Injection Site Reaction
participantsIcatibant 30 mgPlacebo
Erythema3113
Swelling1713
Cutaneous pain107
Burning sensation157
Itching136
Warm sensation168
PrimaryNumber of Participants With Clinically Significant Changes in Laboratory Evaluation, Vital Signs, Electrocardiogram (ECG) and Physical Examination

During laboratory evaluation, serum chemistry and hematology blood tests, and urinalysis were performed. Vital signs parameters included evaluation of pulse rate and systolic and diastolic blood pressure. Standard 12-lead ECGs were performed and ECG recordings were read locally at the study site by a cardiologist. Physical examination was performed with examination of major body systems per routine clinical practice.

Time frame:
Day 0 to Day 5
Reported as:
Number · participants
Number of Participants With Clinically Significant Changes in Laboratory Evaluation, Vital Signs, Electrocardiogram (ECG) and Physical Examination
participantsIcatibant 30 mgPlacebo
Number of Participants With Clinically Significant Changes in Laboratory Evaluation, Vital Signs, Electrocardiogram (ECG) and Physical Examination00
SecondaryTime to Onset of Symptom Relief (TOSR)

TOSR was calculated for the individual symptoms with pre-treatment scores of 2 (moderate) or more improved by at least 1 severity grade and the individual symptoms with pretreatment scores of 0 or 1 (absent or mild) were scored again at 0 or 1 and all the subsequent assessments continued to satisfy this condition. Time-to-event data were summarized using Kaplan-Meier estimates.

Time frame:
Day 0 up to Day 5
Reported as:
Median · days
Time to Onset of Symptom Relief (TOSR)
daysIcatibant 30 mgPlacebo
Time to Onset of Symptom Relief (TOSR)2.00 (0.58 to 3.08)1.55 (0.50 to 3.88)
SecondaryNumber of Participants Experienced Airway Intervention Due to ACE-I-induced Angioedema

Airway Intervention included intubation, tracheotomy, cricothyrotomy.

Time frame:
Day 0 up to Day 5
Reported as:
Number · participants
Number of Participants Experienced Airway Intervention Due to ACE-I-induced Angioedema
participantsIcatibant 30 mgPlacebo
Number of Participants Experienced Airway Intervention Due to ACE-I-induced Angioedema10
SecondaryNumber of Participants Admitted to Hospital or Intensive Care Unit (ICU)

Number of participants with and without an occurrence of admission to the hospital (inpatient) or ICU post-treatment due to the ACE-I-induced angioedema attack were described.

Time frame:
Day 0 up to Day 5
Reported as:
Number · participants
Number of Participants Admitted to Hospital or Intensive Care Unit (ICU)
participantsIcatibant 30 mgPlacebo
Number of Participants Admitted to Hospital or Intensive Care Unit (ICU)2222
SecondaryNumber of Participants Experienced ACE-I-induced Angioedema Attack Following Study Drug Administration

Number of participants with the use of conventional medications (corticosteroids, antihistamines, epinephrine) for the treatment of symptoms of the ACE-I- induced angioedema attack following study drug administration were presented.

Time frame:
Day 0 up to Day 5
Reported as:
Number · participants
Number of Participants Experienced ACE-I-induced Angioedema Attack Following Study Drug Administration
participantsIcatibant 30 mgPlacebo
Number of Participants Experienced ACE-I-induced Angioedema Attack Following Study Drug Administration3535
SecondaryPercentage of Participants With Time to Meeting Discharge Criteria (TMDC) at Specified Time Points

TMDC was based on the investigator-assessed angioedema-associated upper airway symptom assessments. It was calculated from the time of study drug administration to the earliest time point at which the symptoms of difficulty breathing and difficulty swallowing were absent and the symptoms of voice change and tongue swelling were mild or absent and all subsequent assessments continued to satisfy these conditions. These symptoms were evaluated by the investigator using a 5-point grading scale (0=absent, 1=mild, 2=moderate, 3=severe, and 4=very severe). TMDC was analysed using Kaplan-Meier estimates.

Time frame:
4, 6, and 8 hours post treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Time to Meeting Discharge Criteria (TMDC) at Specified Time Points
percentage of participantsIcatibant 30 mgPlacebo
At 4 hours post treatment55.060.3
At 6 hours post treatment78.375.9
At 8 hours post treatment91.791.4
Other pre-specifiedArea Under the Plasma Concentration Versus Time Curve (AUC) of Icatibant and Its Metabolites (M1 and M2)

Area under the plasma concentration-time curve of Icatibant and its metabolites (M1 and M2) were analyzed. A population pharmacokinetic analysis approach using sparse pharmacokinetic sampling obtained from a subset of subjects was used to evaluate exposure to icatibant.

Time frame:
0.75 and 2 hours post-dose
Reported as:
Mean · hours*nanogram per milliliter (h*ng/mL)
Area Under the Plasma Concentration Versus Time Curve (AUC) of Icatibant and Its Metabolites (M1 and M2)
hours*nanogram per milliliter (h*ng/mL)Icatibant 30 mg
Icatibant2530 ± 786
Metabolite M12890 ± 813
Metabolite M23180 ± 931

Adverse events

Collected over From start of study treatment up to Day 5. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Icatibant 30 mg—2/60 (3.3%)14/60 (23.3%)
Placebo—1/58 (1.7%)11/58 (19%)
Most frequent serious events
Most frequent serious events
EventIcatibant 30 mgPlacebo
Rash pruriticSkin and subcutaneous tissue disorders0/601/58
HypoxiaRespiratory, thoracic and mediastinal disorders1/600/58
Laryngeal oedemaRespiratory, thoracic and mediastinal disorders1/600/58
Most frequent other events
Most frequent other events
EventIcatibant 30 mgPlacebo
HeadacheNervous system disorders7/604/58
AngioedemaSkin and subcutaneous tissue disorders7/602/58
NauseaGastrointestinal disorders0/603/58
DyspnoeaRespiratory, thoracic and mediastinal disorders1/603/58
DysphoniaRespiratory, thoracic and mediastinal disorders3/602/58

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)Icatibant 30 mgPlaceboTotal
Mean60.9 ± 12.161.8 ± 13.461.4 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)Icatibant 30 mgPlaceboTotal
Female273562
Male342559
08

Study locations

55 sites
  • University of California San Diego Medical Center
    La Jolla, California 92037, United States
  • University of California San Diego
    La Jolla, California 92093, United States
  • Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • UF Health Shands Hospital
    Gainesville, Florida 32610, United States
  • Orlando Health
    Orlando, Florida 32806, United States
  • Tampa General Hospital
    Tampa, Florida 33606, United States
  • Federal Health Care Center
    Chicago, Illinois 60064-3048, United States
  • Cook County Hospital
    Chicago, Illinois 60612, United States
  • University of Kansas Cancer Center
    Kansas City, Kansas 66160, United States
  • Ochsner Medical Center
    New Orleans, Louisiana 70121, United States
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Womens Hospital
    Boston, Massachusetts 02115, United States
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
  • Detroit Receiving Hospital and University Health Center
    Detroit, Michigan 48201, United States
  • Sinai Grace Hospital
    Detroit, Michigan 48201, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • William Beaumont Hospital
    Troy, Michigan 48085, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55415, United States
  • Barnes Jewish Hospital
    Saint Louis, Missouri 63110, United States
  • Washington University
    Saint Louis, Missouri 63141, United States
  • Inspira Health Network
    Vineland, New Jersey 08360, United States
  • University of New Mexico
    Albuquerque, New Mexico 87106, United States
  • Kings County Hospital Center
    Brooklyn, New York 11203, United States
  • SUNY Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Weill Medical College of Cornell University
    New York, New York 10021, United States
  • East Carolina University
    Greenville, North Carolina 27835, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Ohio State University Hospital - East
    Gahanna, Ohio 43230, United States
  • Summit Health
    Chambersburg, Pennsylvania 17201, United States
  • Hahnemann University Hospital
    Philadelphia, Pennsylvania 19102, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Albert Einstein Medical Center
    Philadelphia, Pennsylvania 19141, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15143, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • University of South Carolina School of Medicine
    Columbia, South Carolina 29203, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • John Peter Smith Hospital
    Fort Worth, Texas 76104, United States
  • University of Texas Medical Branch
    Galveston, Texas 77555-0561, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Queen Elizabeth II Health Sciences Center
    Halifax, Nova Scotia B3H 3A7, Canada
  • Kingston General Hospital
    Kingston, Ontario K7L 2V7, Canada
  • Hotel Dieu Hospital
    Kingston, Ontario K7L 5G2, Canada
  • Soroka University Medical Center
    Beer Sheva, 84101, Israel
  • Bnai Zion Medical Center
    Haifa, 31048, Israel
  • Ziv Medical Center
    Safed, 13100, Israel
  • Tel-Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Brighton and Sussex University Hospitals NHS Trust
    Brighton, BN2 5BE, United Kingdom
  • Royal Devon and Exeter Hospital NHS Trust
    Exeter, EX2 5DW, United Kingdom
  • University Hospital Aintree
    Liverpool, L9 7AL, United Kingdom
  • Manchester Royal Infirmary
    Manchester, M13 9WL, United Kingdom
  • Queen's Medical Centre
    Nottingham, NG7 2UH, United Kingdom
09

References and documents

Publications

  • Sinert R, Levy P, Bernstein JA, Body R, Sivilotti MLA, Moellman J, Schranz J, Baptista J, Kimura A, Nothaft W; CAMEO study group. Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway Angioedema. J Allergy Clin Immunol Pract. 2017 Sep-Oct;5(5):1402-1409.e3. doi: 10.1016/j.jaip.2017.03.003. Epub 2017 May 25. PubMed 28552382 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2013 to primary completion in Aug 2015, 20 months.

Results were first posted in Oct 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2013
First posted
Aug 9, 2013
StartActual
Dec 2, 2013
Primary completionActual
Aug 22, 2015
CompletionActual
Aug 22, 2015
Results first posted
Oct 10, 2016
Last update
Jun 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01919801
Lead sponsor
Shire
Collaborators
PPD DEVELOPMENT, LP
Responsible party
Sponsor
First posted
Aug 9, 2013
Start date
Dec 2, 2013
Primary completion
Aug 22, 2015
Completion
Aug 22, 2015
Results posted
Oct 10, 2016
Last update
Jun 8, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icatibant

Start the discussion